Literature DB >> 24552640

The pathophysiology and pharmacology of hepcidin.

Piotr Ruchala1, Elizabeta Nemeth2.   

Abstract

Inappropriate production of the iron-regulatory hormone hepcidin contributes to the pathogenesis of common iron disorders. Absolute or relative deficiency of hepcidin causes iron overload in hereditary hemochromatosis and iron-loading anemias. Elevated hepcidin causes iron restriction in inflammatory conditions including autoimmune disease, critical illness, some cancers, and chronic kidney disease. Multiple agents targeting hepcidin and its regulators are under development as novel therapeutics for iron disorders. This review summarizes hepcidin biology and discusses the current landscape for hepcidin-targeting therapeutic strategies.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  anemia; ferroportin; iron disorders; iron overload

Mesh：

Substances：

Year:  2014        PMID： 24552640      PMCID： PMC3978192          DOI： 10.1016/j.tips.2014.01.004

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN： 0165-6147            Impact factor:   14.819


  67 in total

1.  Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice.

Authors:  Sara Gardenghi; Pedro Ramos; Maria Franca Marongiu; Luca Melchiori; Laura Breda; Ella Guy; Kristen Muirhead; Niva Rao; Cindy N Roy; Nancy C Andrews; Elizabeta Nemeth; Antonia Follenzi; Xiuli An; Narla Mohandas; Yelena Ginzburg; Eliezer A Rachmilewitz; Patricia J Giardina; Robert W Grady; Stefano Rivella
Journal:  J Clin Invest       Date:  2010-11-22       Impact factor: 14.808

2.  BMP6 treatment compensates for the molecular defect and ameliorates hemochromatosis in Hfe knockout mice.

Authors:  Elena Corradini; Paul J Schmidt; Delphine Meynard; Cinzia Garuti; Giuliana Montosi; Shanzhuo Chen; Slobodan Vukicevic; Antonello Pietrangelo; Herbert Y Lin; Jodie L Babitt
Journal:  Gastroenterology       Date:  2010-08-01       Impact factor: 22.682

3.  Ferroportin and iron regulation in breast cancer progression and prognosis.

Authors:  Zandra K Pinnix; Lance D Miller; Wei Wang; Ralph D'Agostino; Tim Kute; Mark C Willingham; Heather Hatcher; Lia Tesfay; Guangchao Sui; Xiumin Di; Suzy V Torti; Frank M Torti
Journal:  Sci Transl Med       Date:  2010-08-04       Impact factor: 17.956

4.  Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys.

Authors:  Jim J Xiao; Wojciech Krzyzanski; Yow-Ming Wang; Hongyan Li; Mark J Rose; Mark Ma; Yuling Wu; Beth Hinkle; Juan Jose Perez-Ruixo
Journal:  AAPS J       Date:  2010-08-25       Impact factor: 4.009

5.  Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload.

Authors:  Gloria C Preza; Piotr Ruchala; Rogelio Pinon; Emilio Ramos; Bo Qiao; Michael A Peralta; Shantanu Sharma; Alan Waring; Tomas Ganz; Elizabeta Nemeth
Journal:  J Clin Invest       Date:  2011-12       Impact factor: 14.808

6.  Transgenic HFE-dependent induction of hepcidin in mice does not require transferrin receptor-2.

Authors:  Paul J Schmidt; Mark D Fleming
Journal:  Am J Hematol       Date:  2012-03-28       Impact factor: 10.047

Review 7.  Targets of anticytokine therapy and the risk of infections in humans and mice.

Authors:  Esther van de Vosse; Michiel A van Agtmael
Journal:  Curr Opin Rheumatol       Date:  2007-11       Impact factor: 5.006

8.  Posttranslational processing of hepcidin in human hepatocytes is mediated by the prohormone convertase furin.

Authors:  Erika V Valore; Tomas Ganz
Journal:  Blood Cells Mol Dis       Date:  2007-10-01       Impact factor: 3.039

9.  Deletion of TMPRSS6 attenuates the phenotype in a mouse model of β-thalassemia.

Authors:  Antonella Nai; Alessia Pagani; Giacomo Mandelli; Maria Rosa Lidonnici; Laura Silvestri; Giuliana Ferrari; Clara Camaschella
Journal:  Blood       Date:  2012-04-06       Impact factor: 22.113

10.  Blunted hepcidin response to oral iron challenge in HFE-related hemochromatosis.

Authors:  Alberto Piperno; Domenico Girelli; Elizabeta Nemeth; Paola Trombini; Claudia Bozzini; Erika Poggiali; Yen Phung; Tomas Ganz; Clara Camaschella
Journal:  Blood       Date:  2007-08-27       Impact factor: 22.113
View more
  44 in total

1.  Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia.

Authors:  Léon Kautz; Grace Jung; Xin Du; Victoria Gabayan; Justin Chapman; Marc Nasoff; Elizabeta Nemeth; Tomas Ganz
Journal:  Blood       Date:  2015-08-14       Impact factor: 22.113

2.  Iron homeostasis in pregnancy and spontaneous abortion.

Authors:  Yifan Guo; Na Zhang; Daoqiang Zhang; Quanzhong Ren; Tomas Ganz; Sijin Liu; Elizabeta Nemeth
Journal:  Am J Hematol       Date:  2018-11-26       Impact factor: 10.047

3.  Source of iron overload in multiple sclerosis.

Authors:  Diego Di Lorenzo; Giorgio Biasiotto; Isabella Zanella
Journal:  Cell Mol Life Sci       Date:  2014-05-16       Impact factor: 9.261

4.  Chronic inflammation and iron metabolism.

Authors:  Erin A Osterholm; Michael K Georgieff
Journal:  J Pediatr       Date:  2015-02-13       Impact factor: 4.406

5.  Small cyclic agonists of iron regulatory hormone hepcidin.

Authors:  Kristine Chua; Eileen Fung; Ewa D Micewicz; Tomas Ganz; Elizabeta Nemeth; Piotr Ruchala
Journal:  Bioorg Med Chem Lett       Date:  2015-03-12       Impact factor: 2.823

6.  New developments and controversies in iron metabolism and iron chelation therapy.

Authors:  Christina N Kontoghiorghe; George J Kontoghiorghes
Journal:  World J Methodol       Date:  2016-03-26

7.  Hepcidin and risk of anemia in CKD: a cross-sectional and longitudinal analysis in the CKiD cohort.

Authors:  Meredith A Atkinson; Ji Young Kim; Cindy N Roy; Bradley A Warady; Colin T White; Susan L Furth
Journal:  Pediatr Nephrol       Date:  2014-11-08       Impact factor: 3.714

Review 8.  Sepsis: frontiers in diagnosis, resuscitation and antibiotic therapy.

Authors:  Anders Perner; Anthony C Gordon; Daniel De Backer; George Dimopoulos; James A Russell; Jeffrey Lipman; Jens-Ulrik Jensen; John Myburgh; Mervyn Singer; Rinaldo Bellomo; Timothy Walsh
Journal:  Intensive Care Med       Date:  2016-10-01       Impact factor: 17.440

9.  Acute hepatic ischemic-reperfusion injury induces a renal cortical "stress response," renal "cytoresistance," and an endotoxin hyperresponsive state.

Authors:  Richard A Zager; Ali C M Johnson; Kirsten B Frostad
Journal:  Am J Physiol Renal Physiol       Date:  2014-07-30

Review 10.  Molecular liaisons between erythropoiesis and iron metabolism.

Authors:  Leon Kautz; Elizabeta Nemeth
Journal:  Blood       Date:  2014-05-29       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.